Sugi Predict

Sugi Predict / Compounds / SCHEMBL9937467

SCHEMBL9937467

SCHEMBL9937467

CCOC(=O)c1c(C)[nH]c2ccc(F)cc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 4/20 0.72
▸ MAPT P10636 5/20 0.58
▸ PKM P14618 1/20 0.58
▸ LMNA P02545 3/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ HCRTR1 O43613 1/20 0.55
▸ KMT2A Q03164 7/20 0.52
▸ MEN1 O00255 5/20 0.52
▸ HPGD P15428 3/20 0.52
▸ MAPK1 P28482 2/20 0.52
▸ TSHR P16473 1/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.52
▸ ALDH1A1 P00352 3/20 0.51
▸ KDM4E B2RXH2 2/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ MAPK10 P53779 1/20 0.51
▸ HSD17B10 Q99714 1/20 0.51
▸ ALOX5 P09917 4/20 0.50
▸ CYP1A2 P05177 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9938004 0.89 GAA (0.60) GAAMAPTPKMLMNAL3MBTL1
SCHEMBL5236009 0.85 NR4A2 (0.63) GAAMAPTPKMLMNAKMT2A
SCHEMBL2005093 0.84 GAA (1.00) GAAMAPTPKMLMNAKMT2A
SCHEMBL31286098 0.84 GAA (1.00) GAAMAPTPKMLMNAKMT2A
SCHEMBL14830765 0.84 GAA (0.55) GAAMAPTLMNAKMT2AMEN1
SCHEMBL21954408 0.83 GAA (0.72) GAAMAPTPKMLMNAL3MBTL1
SCHEMBL4720481 0.82 GAA (0.71) GAAMAPTPKMLMNAL3MBTL1
SCHEMBL1060499 0.81 KDM5A (0.59) GAAALDH1A1KDM4E
SCHEMBL31485924 0.81 GAA (0.49) GAAMAPTLMNAHCRTR1KMT2A
SCHEMBL21809222 0.80 KEAP1 (0.50) GAAMAPTPKMLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407443-B2 5-HT3 receptor antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-09-10 — — US disclosed
US-20180327421-A1 5-HT3 RECEPTOR ANTAGONISTS ENVOY THERAPEUTICS, INC. 2018-11-15 — — US disclosed
US-10125145-B2 5-HT3 receptor antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-11-13 — — US disclosed
EP-3312169-A1 5-HT3 RECEPTOR ANTAGONISTS Takeda Pharmaceutical Company Limited (JP) 2018-04-25 — — EP disclosed
US-20180072758-A1 5HT3 RECEPTOR ANTAGONISTS TAKEDA CALIFORNIA, INC. 2018-03-15 — — US disclosed
US-20170260201-A1 5-HT3 RECEPTOR ANTAGONISTS ENVOY THERAPEUTICS, INC. 2017-09-14 — — US disclosed
US-9695195-B2 5-HT3 receptor antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-07-04 — — US disclosed
US-9670229-B2 5-HT3 receptor antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-06-06 — — US disclosed
US-20160251373-A1 5-HT3 RECEPTOR ANTAGONISTS ENVOY THERAPEUTICS, INC. 2016-09-01 — — US disclosed
US-20160185801-A1 5-HT3 RECEPTOR ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2016-06-30 — — US disclosed
EP-2875012-A1 5HT3 RECEPTOR ANTAGONISTS Takeda Pharmaceutical Company Limited (JP) 2015-05-27 — — EP disclosed
EP-2875011-A1 5-HT3 RECEPTOR ANTAGONISTS Takeda Pharmaceutical Company Limited (JP) 2015-05-27 — — EP disclosed
US-9012447-B2 5-HT3 receptor antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-21 — — US disclosed
US-8993523-B2 Dimeric IAP inhibitors NOVARTIS AG (CH) 2015-03-31 — — US disclosed
WO-2014014951-A1 5-HT3 RECEPTOR ANTAGONISTS ENVOY THERAPEUTICS, INC. (US) 2014-01-23 — — WO disclosed
WO-2014014962-A1 5HT3 RECEPTOR ANTAGONISTS ENVOY THERAPEUTICS, INC. (US) 2014-01-23 — — WO disclosed
US-20140024644-A1 5-HT3 RECEPTOR ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-01-23 — — US disclosed
US-20130309247-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2013-11-21 — — US disclosed
EP-2651919-A1 DIMERIC IAP INHIBITORS Novartis AG (CH) 2013-10-23 — — EP disclosed
WO-2012080271-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2012-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10407443-B2 5-HT3 receptor antagonists HTR3A, HTR3B, HTR5A GAA 1758/4885MAPT 1157/4885PKM 2782/4885
US-20160185801-A1 5-HT3 RECEPTOR ANTAGONISTS HTR3A, HTR5A, HTR3B GAA 1774/4885MAPT 1038/4885PKM 2689/4885
US-20170260201-A1 5-HT3 RECEPTOR ANTAGONISTS HTR3A, HTR3B, HTR5A GAA 1758/4885MAPT 1157/4885PKM 2782/4885
US-20130309247-A1 DIMERIC IAP INHIBITORS XIAP, BIRC5, BIRC2 GAA 1947/4885MAPT 1235/4885PKM 2627/4885
US-20180327421-A1 5-HT3 RECEPTOR ANTAGONISTS HTR3A, HTR3B, HTR5A GAA 1758/4885MAPT 1157/4885PKM 2782/4885
US-20140024644-A1 5-HT3 RECEPTOR ANTAGONISTS HTR3A, HTR3B, HTR5A GAA 1758/4885MAPT 1157/4885PKM 2782/4885
US-20180072758-A1 5HT3 RECEPTOR ANTAGONISTS HTR3A, HTR3B, HTR5A GAA 1767/4885MAPT 1056/4885PKM 2535/4885
US-20160251373-A1 5-HT3 RECEPTOR ANTAGONISTS HTR3A, HTR3B, HTR5A GAA 1758/4885MAPT 1157/4885PKM 2782/4885
US-10125145-B2 5-HT3 receptor antagonists HTR3A, HTR3B, HTR5A GAA 1758/4885MAPT 1157/4885PKM 2782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.